KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash & Equivalents: 2011-2025

Historic Cash & Equivalents for Sarepta Therapeutics (SRPT) over the last 15 years, with Sep 2025 value amounting to $613.1 million.

  • Sarepta Therapeutics' Cash & Equivalents rose 209.87% to $613.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $613.1 million, marking a year-over-year increase of 209.87%. This contributed to the annual value of $1.1 billion for FY2024, which is 19.60% down from last year.
  • As of Q3 2025, Sarepta Therapeutics' Cash & Equivalents stood at $613.1 million, which was down 8.96% from $673.4 million recorded in Q2 2025.
  • Sarepta Therapeutics' Cash & Equivalents' 5-year high stood at $2.1 billion during Q4 2021, with a 5-year trough of $197.9 million in Q3 2024.
  • In the last 3 years, Sarepta Therapeutics' Cash & Equivalents had a median value of $613.1 million in 2025 and averaged $695.3 million.
  • As far as peak fluctuations go, Sarepta Therapeutics' Cash & Equivalents tumbled by 63.49% in 2024, and later skyrocketed by 209.87% in 2025.
  • Sarepta Therapeutics' Cash & Equivalents (Quarterly) stood at $2.1 billion in 2021, then crashed by 54.31% to $966.8 million in 2022, then soared by 41.91% to $1.4 billion in 2023, then fell by 19.60% to $1.1 billion in 2024, then skyrocketed by 209.87% to $613.1 million in 2025.
  • Its Cash & Equivalents stands at $613.1 million for Q3 2025, versus $673.4 million for Q2 2025 and $612.3 million for Q1 2025.